Collaboration License Agreement for the Development and Commercialization of Integrin Peptide Therapy
Senju Pharmaceutical Co., Ltd. and Allegro Ophthalmics, LLC today announced that they have entered into a collaboration and license agreement to develop and market Allegro’s Integrin Peptide Therapy in Japan. Integrin Peptide Therapy uniquely approaches multiple indications by collectively turning off the production of aberrant blood vessels, reducing the leakage of aberrant blood vessels, and inhibiting the growth of aberrant blood vessels due to its unique mechanism of action.
Under the terms of the agreement, Senju will acquire the rights to co-develop and market Allegro’s Integrin Peptide Therapy in Japan. In exchange for these rights, Senju have agreed to pay Allegro an upfront license fee, additional development and sales milestone fees, and a percentage royalty on net sales.
Allegro Ophthalmics, LLC is establishing Integrin Peptide Therapy as the next-generation pharmaceutical category for the treatment of wet age-related macular degeneration, diabetic retinopathy and diabetic macular edema.